Rebecca A Nelson1, Zeynep Bostanci2, Veronica Jones2, Joanne Mortimer3, Amy Polverini2, Lesley Taylor2, Lisa Yee2, John H Yim2, Laura Kruper4. 1. Department of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, CA, USA. 2. Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA. 3. Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA. 4. Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA. lkruper@coh.org.
Abstract
BACKGROUND AND PURPOSE: The Breast and Cervical Cancer Treatment Program (BCCTP) Act, passed by Congress in 2000, provides time-limited coverage to uninsured breast or cervical cancer patients. We examine survival differences between BCCTP cases and insured controls. METHODS: Stage I-III breast cancer patients, covered under California's BCCTP from 2005 to 2009 (N = 6343), were 1:1 matched with California Cancer Registry controls on age, race/ethnicity, and cancer stage. Overall and disease-specific (OS and DSS) survival were compared using multivariate regression. RESULTS: BCCTP cases were more often unmarried [odds ratio (OR) 2.47, 95% confidence interval (CI) 2.30-2.66], with poorly/undifferentiated tumors (OR 1.26, CI 1.13-1.40), classified as ER negative (OR 1.10, CI 1.02-1.20) and/or PR negative (OR 1.09, CI 1.01-1.17). Cases were more likely to undergo mastectomy (OR 1.13, CI 1.05-1.21) or no surgery (OR 1.64, CI 1.31-2.05) versus lumpectomy. Cases were also more likely to undergo radiation (OR 1.11, CI 1.03-1.19). Endocrine therapy rates were marginally lower in cases (OR 0.93, CI 0.86-1.00). OS and DSS were shorter in BCCTP cases on multivariate analysis (HR 1.29, CI 1.17-1.42 and HR 1.27, CI 1.14-1.42, respectively). When stratified by socioeconomic status (SES), cases had significantly shorter OS and DSS except in the lowest quintile. When stratified by stage, cases had significantly shorter OS and DSS, except for stage I. CONCLUSIONS: The BCCTP provides uninsured breast cancer patients with comprehensive and timely care. Although our results suggest that BCCTP delivers quality care, BCCTP patients have shorter survival rates, even after accounting for SES and stage differences. Further assistance to vulnerable populations is warranted, including longer duration of treatment coverage, and surveillance adhering to NCCN compliant surveillance programs.
BACKGROUND AND PURPOSE: The Breast and Cervical Cancer Treatment Program (BCCTP) Act, passed by Congress in 2000, provides time-limited coverage to uninsured breast or cervical cancer patients. We examine survival differences between BCCTP cases and insured controls. METHODS: Stage I-III breast cancer patients, covered under California's BCCTP from 2005 to 2009 (N = 6343), were 1:1 matched with California Cancer Registry controls on age, race/ethnicity, and cancer stage. Overall and disease-specific (OS and DSS) survival were compared using multivariate regression. RESULTS: BCCTP cases were more often unmarried [odds ratio (OR) 2.47, 95% confidence interval (CI) 2.30-2.66], with poorly/undifferentiated tumors (OR 1.26, CI 1.13-1.40), classified as ER negative (OR 1.10, CI 1.02-1.20) and/or PR negative (OR 1.09, CI 1.01-1.17). Cases were more likely to undergo mastectomy (OR 1.13, CI 1.05-1.21) or no surgery (OR 1.64, CI 1.31-2.05) versus lumpectomy. Cases were also more likely to undergo radiation (OR 1.11, CI 1.03-1.19). Endocrine therapy rates were marginally lower in cases (OR 0.93, CI 0.86-1.00). OS and DSS were shorter in BCCTP cases on multivariate analysis (HR 1.29, CI 1.17-1.42 and HR 1.27, CI 1.14-1.42, respectively). When stratified by socioeconomic status (SES), cases had significantly shorter OS and DSS except in the lowest quintile. When stratified by stage, cases had significantly shorter OS and DSS, except for stage I. CONCLUSIONS: The BCCTP provides uninsured breast cancer patients with comprehensive and timely care. Although our results suggest that BCCTP delivers quality care, BCCTP patients have shorter survival rates, even after accounting for SES and stage differences. Further assistance to vulnerable populations is warranted, including longer duration of treatment coverage, and surveillance adhering to NCCN compliant surveillance programs.
Authors: Jennifer L Malin; Allison L Diamant; Barbara Leake; Yihang Liu; Amardeep Thind; Katherine L Kahn; Eric C Schneider; Arnold M Epstein; Rose C Maly Journal: J Clin Oncol Date: 2010-06-07 Impact factor: 44.544
Authors: Melissa J Liu; Helen Hawk; Susan T Gershman; Suzanne M Smith; Ruth Karacek; Mary Lou Woodford; John Z Ayanian Journal: Cancer Causes Control Date: 2005-02 Impact factor: 2.506
Authors: Ayal A Aizer; Ming-Hui Chen; Ellen P McCarthy; Mallika L Mendu; Sophia Koo; Tyler J Wilhite; Powell L Graham; Toni K Choueiri; Karen E Hoffman; Neil E Martin; Jim C Hu; Paul L Nguyen Journal: J Clin Oncol Date: 2013-09-23 Impact factor: 44.544
Authors: Lisa A Newman; James Mason; David Cote; Yael Vin; Kathryn Carolin; David Bouwman; Graham A Colditz Journal: Cancer Date: 2002-06-01 Impact factor: 6.860